Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Metastasis | Primary research

ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway

Authors: Yanqiu Bao, Jingshu Cui, Yuyang Yue, Shuxia Cao, Xiangdan Li, Lan Liu

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Malignant melanoma (MM) is highly metastatic and has the highest mortality rate in patients with skin cancer. The ERBB3 binding protein 1 (Ebp1) has been linked to the onset and progression of a number of malignancies. However, the role of Ebp1 in MM has not yet been reported.

Methods

Multiple databases were analyzed for comparing the expression of Ebp1 in normal skin and MM. Ebp1 expression was knocked down in A375 and B16 cells, and the impact of Ebp1 on the cell growth was tested by CCK-8, plate clone colony, and cell cycle assays. Scratch, transwell, and in vivo caudal vein lung metastasis tests were also used to confirm the effects of Ebp1 on melanoma cells migration, invasion, and metastasis. Furthermore, the possible molecular mechanism of Ebp1 was predicted by set enrichment analysis and verified by western blotting.

Results

Ebp1 expression was substantially higher in MM than it was in normal skin, and Ebp1 was linked to the clinical stage and lymph node metastases of patients with MM. Knockdown of Ebp1 inhibited cell proliferation, migration, and invasion. In vivo experiments further verified that the knockdown of Ebp1 had an obvious inhibitory effect on lung metastasis in nude mice. Knockdown of Ebp1 reduced vimentin, N-cadherin, slug, and snail expression while increasing E-cadherin expression. Furthermore, knockdown of Ebp1 reduced the expression of β-catenin, as well as its downstream targets CyclinD1 and p-GSK3β; however, a Wnt/β-catenin agonist could reverse this effect.

Conclusion

Ebp1 may promote the proliferation and metastasis of melanoma cells through activation of the Wnt/β-catenin pathway.

Graphical Abstract

Corrie P, Hategan M, Fife K, Parkinson C. Management of melanoma. Br Med Bull. 2014;111(1):149–62. https://doi.org/10.1093/bmb/ldu019.CrossRefPubMed

Stege H, Haist M, Nikfarjam U, Schultheis M, Heinz J, Pemler S, Loquai C, Grabbe S. The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges. Target Oncol. 2021;16(5):537–52. https://doi.org/10.1007/s11523-021-00840-3.CrossRefPubMedPubMedCentral

Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135(6):807–10. https://doi.org/10.1016/0002-9610(78)90171-x.CrossRefPubMed

Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16(1):5–24. https://doi.org/10.1634/theoncologist.2010-0190.CrossRefPubMedPubMedCentral

Hodorogea A, Calinescu A. Epithelial-mesenchymal transition in skin cancers: a review. Anal Cell Pathol. 2019;2019:3851576. https://doi.org/10.1155/2019/3851576.CrossRef

Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8. https://doi.org/10.1126/scisignal.2005189.CrossRefPubMedPubMedCentral

Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81. https://doi.org/10.1083/jcb.200601018.CrossRefPubMedPubMedCentral

Hiremath IS, Goel A, Warrier S, Kumar AP, Sethi G. The multidimensional role of the Wnt/β-catenin signaling pathway in human malignancies. J Cell Physiol. 2021. https://doi.org/10.1002/jcp.30561.CrossRefPubMed

Hwang I, Ko HR, Ahn JY. The roles of multifunctional protein ErbB3 binding protein 1 (EBP1) isoforms from development to disease. Exp Mol Med. 2020;52(7):1039–47. https://doi.org/10.1038/s12276-020-0476-z.CrossRefPubMedPubMedCentral

10.

Stevenson BW, Gorman MA, Koach J, Cheung BB, Marshall GM, Parker MW, Holien JK. A structural view of PA2G4 isoforms with opposing functions in cancer. J Biol Chem. 2020;295(47):16100–12. https://doi.org/10.1074/jbc.REV120.014293.CrossRefPubMedPubMedCentral

11.

Kim CK, Nguyen TL, Joo KM, Nam DH, Park J, Lee KH, Cho SW, Ahn JY. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Can Res. 2010;70(23):9730–41. https://doi.org/10.1158/0008-5472.can-10-1882.CrossRef

12.

Nguyen DQ, Hoang DH, Nguyen TTV, Ho HD, Huynh V, Shin JH, Ly QT, Thi Nguyen DD, Ghoda L, Marcucci G, et al. Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIF-90-mediated ribosomal RNA synthesis. J Cell Physiol. 2019;234(10):17612–21. https://doi.org/10.1002/jcp.28385.CrossRefPubMed

13.

Bao Y, Suvesh M, Li X, Bai X, Li H, Li X, Xu D. Ebp1 p48 promotes oncogenic properties in hepatocellular carcinoma through p38 MAPK/HIF1α activation and p53 downregulation. Mol Carcinogen. 2021;60(4):252–64. https://doi.org/10.1002/mc.23288.CrossRef

14.

le Nguyen XT, Zhu L, Lee Y, Ta L, Mitchell BS. Expression and role of the ErbB3-binding protein 1 in acute myelogenous leukemic cells. Clin Cancer Res. 2016;22(13):3320–7. https://doi.org/10.1158/1078-0432.ccr-15-2282.CrossRef

15.

Ou K, Kesuma D, Ganesan K, Yu K, Soon SY, Lee SY, Goh XP, Hooi M, Chen W, Jikuya H, et al. Quantitative profiling of drug-associated proteomic alterations by combined 2-nitrobenzenesulfenyl chloride (NBS) isotope labeling and 2DE/MS identification. J Proteome Res. 2006;5(9):2194–206. https://doi.org/10.1021/pr060115n.CrossRefPubMed

16.

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA. 2005;102(28):9890–5. https://doi.org/10.1073/pnas.0503829102.CrossRefPubMedPubMedCentral

17.

Hwang I, Kim CK, Ko HR, Park KW, Cho SW, Ahn JY. C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth. Sci Rep. 2016;6:30626. https://doi.org/10.1038/srep30626.CrossRefPubMedPubMedCentral

18.

Ko HR, Nguyen TL, Kim CK, Park Y, Lee KH, Ahn JY. P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer. BMB Rep. 2015;48(3):159–65. https://doi.org/10.5483/bmbrep.2015.48.3.130.CrossRefPubMedPubMedCentral

19.

Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, et al. Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol Cell. 2015;59(1):75–88. https://doi.org/10.1016/j.molcel.2015.05.009.CrossRefPubMedPubMedCentral

20.

McNally RJQ, Basta NO, Errington S, James PW, Norman PD, Craft AW. Socioeconomic patterning in the incidence and survival of children and young people diagnosed with malignant melanoma in northern England. J Invest Dermatol. 2014;134(11):2703–8. https://doi.org/10.1038/jid.2014.246.CrossRefPubMed

21.

Radomski N, Jost E. Molecular cloning of a murine cDNA encoding a novel protein, p38–2G4, which varies with the cell cycle. Exp Cell Res. 1995;220(2):434–45. https://doi.org/10.1006/excr.1995.1335.CrossRefPubMed

22.

Liu Z, Ahn JY, Liu X, Ye K. Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci USA. 2006;103(29):10917–22. https://doi.org/10.1073/pnas.0602923103.CrossRefPubMedPubMedCentral

23.

Ko HR, Hwang I, Ahn SY, Chang YS, Park WS, Ahn JY. Neuron-specific expression of p48 Ebp1 during murine brain development and its contribution to CNS axon regeneration. BMB Rep. 2017;50(3):126–31. https://doi.org/10.5483/bmbrep.2017.50.3.190.CrossRefPubMedPubMedCentral

24.

Mei Y, Zhang P, Zuo H, Clark D, Xia R, Li J, Liu Z, Mao L. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis. Oncogene. 2014;33(29):3839–50. https://doi.org/10.1038/onc.2013.354.CrossRefPubMed

25.

Ko HR, Kim CK, Ahn JY. Phosphorylation of the N-terminal domain of p48 Ebp1 by CDK2 is required for tumorigenic function of p48. Mol Carcinog. 2015;54(11):1283–91. https://doi.org/10.1002/mc.22203.CrossRefPubMed

26.

Pisapia L, Barba P, Cortese A, Cicatiello V, Morelli F, Del Pozzo G. EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells. Int J Oncol. 2015;47(2):481–9. https://doi.org/10.3892/ijo.2015.3051.CrossRefPubMedPubMedCentral

27.

Hoesl C, Fröhlich T, Posch C, Kneitz H, Goebeler M, Schneider MR, Dahlhoff M. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis. Mol Oncol. 2021;15(8):2140–55. https://doi.org/10.1002/1878-0261.12945.CrossRefPubMedPubMedCentral

28.

Tiwary S, Preziosi M, Rothberg PG, Zeitouni N, Corson N, Xu L. ERBB3 is required for metastasis formation of melanoma cells. Oncogenesis. 2014;3(7): e110. https://doi.org/10.1038/oncsis.2014.23.CrossRefPubMedPubMedCentral

29.

Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30(10):764–76. https://doi.org/10.1016/j.tcb.2020.07.003.CrossRefPubMedPubMedCentral

30.

Pedri D, Karras P, Landeloos E, Marine JC. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 2021. https://doi.org/10.1111/febs.16021.CrossRefPubMed

31.

Untiveros G, Dezi L, Gillette M, Sidor J, Strizzi L. Normal skin cells increase aggressiveness of cutaneous melanoma by promoting epithelial-to-mesenchymal transition via nodal and Wnt activity. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms222111719.CrossRefPubMedPubMedCentral

32.

Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene. 2007;26(16):2290–8. https://doi.org/10.1038/sj.onc.1210029.CrossRefPubMed

33.

Gottardi CJ, Gumbiner BM. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol. 2004;167(2):339–49. https://doi.org/10.1083/jcb.200402153.CrossRefPubMedPubMedCentral

34.

Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83. https://doi.org/10.1038/35000025.CrossRefPubMed

35.

Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511. https://doi.org/10.1242/jcs.00224.CrossRefPubMed

36.

Wong TS, Gao W, Chan JY. Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors. Biomed Res Int. 2014;2014: 921564. https://doi.org/10.1155/2014/921564.CrossRefPubMedPubMedCentral

37.

Lee HM, Hwang KA, Choi KC. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process. Mol Cell Endocrinol. 2017;457:103–13. https://doi.org/10.1016/j.mce.2016.12.026.CrossRefPubMed

38.

Sharma A, Mir R, Galande S. Epigenetic regulation of the Wnt/β-catenin signaling pathway in cancer. Front Genet. 2021;12: 681053. https://doi.org/10.3389/fgene.2021.681053.CrossRefPubMedPubMedCentral

39.

Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99. https://doi.org/10.1016/j.cell.2017.05.016.CrossRef

40.

Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signalling pathway. Nature. 1998;396(6709):370–3. https://doi.org/10.1038/24620.CrossRefPubMed

41.

Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R, Ben-Ze’ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96(10):5522–7. https://doi.org/10.1073/pnas.96.10.5522.CrossRefPubMedPubMedCentral

42.

Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Molecular pathology : MP. 1999;52(3):151–7. https://doi.org/10.1136/mp.52.3.151.CrossRefPubMedCentral

43.

Gajos-Michniewicz A, Czyz M. WNT signaling in melanoma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21144852.CrossRefPubMedPubMedCentral

44.

Chen W, Zhao S, Yu W, Rao T, Ruan Y, Zhu S, Xia Y, Song H, Cheng F. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway. J Cell Mol Med. 2021;25(22):10684–97. https://doi.org/10.1111/jcmm.17005.CrossRefPubMedPubMedCentral

45.

Ji C, Yang L, Yi W, Xiang D, Wang Y, Zhou Z, Qian F, Ren Y, Cui W, Zhang X, et al. Capillary morphogenesis gene 2 maintains gastric cancer stem-like cell phenotype by activating a Wnt/β-catenin pathway. Oncogene. 2018;37(29):3953–66. https://doi.org/10.1038/s41388-018-0226-z.CrossRefPubMedPubMedCentral

46.

Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205. https://doi.org/10.1016/j.cell.2012.05.012.CrossRef

47.

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. https://doi.org/10.1186/s13045-017-0471-6.CrossRefPubMedPubMedCentral

48.

Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997;16(13):3797–804. https://doi.org/10.1093/emboj/16.13.3797.CrossRefPubMedPubMedCentral

49.

Wei A, Fan B, Zhao Y, Zhang H, Wang L, Yu X, Yuan Q, Yang D, Wang S. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway. Oncotarget. 2016;7(40):65374–88. https://doi.org/10.18632/oncotarget.11699.CrossRefPubMedPubMedCentral

50.

Liu CC, Cai DL, Sun F, Wu ZH, Yue B, Zhao SL, Wu XS, Zhang M, Zhu XW, Peng ZH, et al. FERMT1 mediates epithelial-mesenchymal transition to promote colon cancer metastasis via modulation of β-catenin transcriptional activity. Oncogene. 2017;36(13):1779–92. https://doi.org/10.1038/onc.2016.339.CrossRefPubMed

Title: ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway
Authors: Yanqiu Bao
Jingshu Cui
Yuyang Yue
Shuxia Cao
Xiangdan Li
Lan Liu
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Metastasis
Melanoma
Melanoma
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02473-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Knockdown of RSPH14 inhibits proliferation, migration, and invasion and promotes apoptosis of hepatocellular carcinoma via RelA

DNA methyltransferase 1 inhibits microRNA-497 and elevates GPRC5A expression to promote chemotherapy resistance and metastasis in breast cancer

Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer

HPV16 E6 gene polymorphisms and the functions of the mutation site in cervical cancer among Uygur ethnic and Han nationality women in Xinjiang, China

DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways

Emerging role of non-coding RNAs in the regulation of KRAS

Keynote webinar | Spotlight on antibody–drug conjugates in cancer